When is the next results date for Asston Pharmaceu?

Asston Pharmaceu is scheduled to announce its results on 14 November 2025.

Asston Pharmaceu is scheduled to declare its results on 14 November 2025.

How has been the historical performance of Asston Pharmaceu?

Asston Pharmaceu experienced significant growth from March 2024 to March 2025, with net sales rising to 25.04 Cr from 15.59 Cr, and profit after tax increasing to 4.33 Cr from 1.36 Cr. Key metrics such as EPS improved to 6.91 and operating profit margin rose to 24.64%, indicating a strengthening financial position.

Answer:<BR>The historical performance of Asston Pharmaceu shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Asston Pharmaceu reported net sales of 25.04 Cr in March 2025, a notable increase from 15.59 Cr in March 2024. Total operating income also rose to 25.04 Cr from 15.59 Cr, driven by an increase in raw material costs to 14.13 Cr from 9.75 Cr. The total expenditure, excluding depreciation, increased to 18.87 Cr from 13.04 Cr, resulting in an operating profit (PBDIT) of 6.74 Cr, up from 2.80 Cr. Profit before tax surged to 5.70 Cr from 1.82 Cr, leading to a profit after tax of 4.33 Cr, compared to 1.36 Cr the previous year. The earnings per share (EPS) improved significantly to 6.91 from 2.18, while the operating profit margin increased to 24.64% from 16.36%. The total assets of the company grew to 28.10 Cr from 20.70 Cr, with total liabilities also rising to 28.10 Cr from 20.70 Cr. The book value per share adjusted increased to 17.6 from 11.45, reflecting the company's strengthening financial position.

Is Asston Pharmaceu overvalued or undervalued?

As of November 26, 2025, Asston Pharmaceu is considered overvalued with a PE ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35, despite outperforming the Sensex with a 1-week return of 17.65%.

As of 26 November 2025, Asston Pharmaceu's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a price-to-earnings (PE) ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35. These metrics suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Asston Pharmaceu's PE ratio is lower than that of Sun Pharma (37.53) and Divi's Lab (69.71), both categorized as expensive, while it is slightly higher than Cipla (22.59) and Dr. Reddy's Labs (18.02), which are viewed as attractive. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 17.65% compared to the Sensex's 0.50%, reinforcing the notion of overvaluation in the current market context.

Which are the latest news on Asston Pharmaceu?

Why is Asston Pharmaceu falling/rising?

As of 04-Dec, Asston Pharmaceuticals Ltd's stock price is currently 96.99, reflecting a 2.02% decrease and a significant drop in investor participation. Despite past outperformance, recent trends indicate a downward movement in the stock price.

As of 04-Dec, Asston Pharmaceuticals Ltd's stock price is falling, currently at 96.99, which represents a decrease of 2.0 (-2.02%). The stock has been underperforming, having lost 7.29% over the last two days and opened today with a significant gap down of 5.81%. Additionally, the stock has shown a decline in investor participation, with delivery volume dropping by 48.41% compared to the 5-day average. Although the stock has performed well over the past week and month, outperforming the Sensex, the current negative trends in daily performance and investor engagement indicate a downward movement in the stock price.